Tislelizumab, a humanized IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody approved in China in 2019 for advanced solid tumors such as esophageal cancer, functions by blocking the PD-1/PD-L1 pathway to reactivate anti-tumor immunity. This evidence concerns the gene PDCD1 and esophageal cancer.